Drug intelligence / Profile preview

PP-CT03

Development stage: Unknown
Lead developer: Pila Pharma
Modality: Small Molecules
Administration: Oral

Overview

PP-CT03 is an oral, first-in-class TRPV1 antagonist developed by the Swedish biopharma company Pila Pharma. It is currently undergoing a Phase 2a clinical trial, conducted by Lindus Health, for the treatment of obesity and type 2 diabetes. Lindus Health is responsible for the full study execution, including regulatory applications, patient recruitment, and monitoring.

Targets

TRPV1 (Transient receptor potential cation channel subfamily V member 1)

Beyond the preview

Go deeper on PP-CT03.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PP-CT03.

Explore the full profile